[1]魏莉,罗荣城.放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展[J].国际放射医学核医学杂志,2006,30(3):153-157.
　WEI Li,LUO Rong-cheng.Advances in research of radioactive nuclide labeled anti-CD20 monoclonal antibody in B cell lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):153-157.
点击复制

放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
30
期数:
2006年第3期
页码:
153-157
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Advances in research of radioactive nuclide labeled anti-CD20 monoclonal antibody in B cell lymphomas
作者:
魏莉;  罗荣城
510515 广州, 南方医科大学南方医院肿瘤中心
Author(s):
WEI Li;  LUO Rong-cheng
Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
关键词:
放射免疫疗法; 淋巴瘤; B细胞; 抗原; CD20; 抗体; 抗独特型; 放射性同位素
Keywords:
Radioimmunotherapy; Lymphomas; B cell; Antigens; CD20; Antibodies; anti-idiotypic; Radioisotope
分类号:
R817.5
摘要:
放射免疫治疗(radioimmunotherapy,RIT)属于内照射治疗,可以用较少的单克隆抗体耦联放射性核素,在肿瘤局部产生足够的电离辐射生物学效应,达到高效低毒的治疗效果。B细胞淋巴瘤有较高的复发比例,其CD20抗原表达率达90%以上,且不易从细胞膜上脱落,因此131I-利妥昔单抗CD20是B细胞淋巴瘤放免治疗的最佳靶点。目前已有数个放免治疗的药物,如:131I-托西莫单抗(131I-tositumomab)、131I-Rituximab、90Y-替坦异贝莫单抗(90Y-ibritumomabtiuxetan)等,用于B细胞淋巴瘤的临床治疗,它们具有各自的优缺点。使用结果表明:肿瘤部位的高吸收剂量保证了治疗的有效性,其对非靶器官的照射剂量是安全的。最主要的副反应包括:血小板减少症、中性粒细胞减少症、胃肠道反应及甲状腺功能减低症。在取得满意结果的同时,B细胞淋巴瘤放免治疗仍存在许多问题,人们正致力于更进一步的研究解决此类问题,以取得更好的治疗效果。
Abstract:
Radioimmunotherapy(RIT), a kind of internal radiation therapy, can achieve high performance and low toxicity by fewer monoclonal antibodys couple radioactive nuclides, created sufficient ionization biologic effect on tumor. B cell lymphomas has higher relapsed rate, CD20 is the best target of RIT on B cell lymphomas because the expression rate of it on B cell lymphomas is above 90%, and it is not desquamated easily. There are severy drug of RIT, such as 131I-tositumomab, 131I-Rituximab, and 90Y-ibritumomab tiuxetan. Each one has its advantages and disadvantages. Clinical trials indicates they are effective on B cell lymphomas, and safe to non-targetted organs. The main side effects include thrombopenia, neutropenia, gastrointestinal tract response, and hypothyroidism. While satisfied results have attained, many problems are existed. All researchers do their best to resolve there problems for better therapy results.

参考文献/References:

1 Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies.J Lab Clin Med, 1999, 134(5):445-450.
2 Hainsworth JD. Monoclonal antibody therapy in lymphoid malignancies. Oncologist, 2000, 5(5):376-384.
3 Press OW, Eary JF, Cooley T, et al. A phase Ⅰ/Ⅱ trial of iodine-131-tositumomab(anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood, 2000, 96(9):2934-2942.
4 Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol, 2005, 23(3):461-467.
5 Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 2005, 352(5):441-449.
6 Seldin DW. Techniques for using Bexxar for the treatment of non-Hodgkin’s lymphoma. Nucl Med Technol, 2002, 30(3):109-114.
7 Nair M, Mark R, Anderson P, et al. Bexxar Protocol CP98-020:Preliminary results with 131I-labeled antibody in patients with non-Hodgkin’s lymphoma refractory to chemotherapy and rituxan.Orlando, FL:ASCO, 2005. 612.
8 Gregory A J, Leonard PJ, Vose M, et al. Superior outcomes associated with earlier use:Experience with tositumomab and iodine 131I-tositumomab in 1177 patients with low-grade, follicular,and transformed non-Hodgkin’s lymphoma (NHL). Orlando, FL:ASCO, 2005. 575.
9 Turner JH, Martindale AA, Boucek J, et al. 131I-Anti CD20 radioimmunotherapy of relapsed or refraclory non-Hodgkin’s lymphoma:a phase Ⅱ clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm, 2003, 18(4):513-524.
10 张军一, 罗海涛, 李爱民, 等.131I-美罗华治疗难治性复发性B细胞淋巴瘤9例.解放军医学杂志,2003,28(2):190.
11 Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol, 2002, 20(15):3262-3269.
12 Joyce J, Schuster MW, McCook B, et al. Experience with yttrium-90 ibritumomab tiuxetan (Zevalin) after autologous stem cell transplant(ASCT) in patients with non-Hodgkin’s lymphoma (NHL). Orlando,FL:ASCO, 2005. 602.
13 Shipley DL, Greco FA, Spigel DR, et al. Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma:Update of a Minnie Pearl Cancer Research Network phase Ⅱ trial. Orlando,FL:ASCO, 2005. 579.
14 Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade,follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol,2003, 21(7):1263-1270.

相似文献/References:

[1]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
　Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[2]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
　You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[3]胡娜,吴永港,肖立志,等.18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
　Hu Na,Wu Yonggang,Xiao Lizhi,et al.Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
[4]戴娜,吴翼伟.影像学技术在霍奇金淋巴瘤诊疗中的价值[J].国际放射医学核医学杂志,2014,38(2):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
　Dai Na,Wu Yiwei.The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
[5]郭艾楠,魏玲格,傅鹏.131I-肿瘤细胞核人鼠嵌合单克隆抗体治疗实体瘤的研究进展[J].国际放射医学核医学杂志,2013,37(2):120.[doi:10.3760/cma.j.issn.1673-4114.2013.02.015]
　GUO Ai-nan,WEI Ling-ge,FU Peng.Advances on the treatment of solid tumor by 131I labeled mouse-human chimeric tumor necrosis therapy monoclanal antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):120.[doi:10.3760/cma.j.issn.1673-4114.2013.02.015]
[6]杨希,党春江.泌尿系统原发性结外淋巴瘤的临床及影像学表现[J].国际放射医学核医学杂志,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
　YANG Xi,DANG Chun-jiang.The clinical and imaging appearances of primary extranodal lymphoma of the urinary system[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
[7]李艳梅,杨建伟,李鹏,等.单眼虹膜原发非霍奇金淋巴瘤18F-FDGPET/CT显像及疗效评价一例[J].国际放射医学核医学杂志,2013,37(5):326.[doi:10.3760/cma.j.issn.1673-4114.2013.05.017]
[8]萨日,赵红光,关锋,等.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2013,37(1):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
　SA Ri,ZHAO Hong-guang,GUAN Feng,et al.Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
[9]姚红霞,张金山.微波消融和131I-肿瘤细胞核人鼠嵌合单克隆抗体联合治疗肺癌[J].国际放射医学核医学杂志,2012,36(5):264.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.002]
　YAO Hong-xia,ZHA NG Jin-shan.Combination of microwave ablation and 131I labeled tumor necrosis therapy chimeric antibody in the treatment of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):264.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.002]
[10]王月英,吴红英,李德冠,等.小鼠不同肿瘤模型对放化疗敏感性的研究[J].国际放射医学核医学杂志,2012,36(5):289.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.006]
　WANG Yue-ying,WU Hong-ying,LI De-guan,et al.The radiation sensitivities of different mice tumor model to radiotherapy and chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):289.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.006]
[11]蔡秋琼,杜明华.131Ⅰ-rituximab治疗B细胞非霍奇金淋巴瘤[J].国际放射医学核医学杂志,2008,32(2):72.
　CAI Qiu-qiong,DU Ming-hua.131Ⅰ-rituximab therapy of B cell non-Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):72.
[12]于晓明,樊飞跃.肿瘤放射免疫疗法研究进展[J].国际放射医学核医学杂志,2006,30(2):80.
　YU Xiao-ming,FAN Fei-yue.Recent developments in radioimmunotherapy of tumor[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):80.

备注/Memo

备注/Memo:
收稿日期:2005-08-30。
通讯作者:罗荣城(E-mail:lrc@nfhoc.com)
更新日期/Last Update: 1900-01-01